Luebeck

• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease Ended recruitment
  2023-506880-32-01 1 2025-04-14 Pulmonary Disease, Chronic Obstructive
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsor … Ended recruitment
  2024-517830-17-00 4 2025-03-14 Chronic Urticaria
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation t … Ended recruitment
  2023-510458-18-00 6 2025-03-11 Asthma
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) Ended recruitment
  2024-513384-15-00 4 2025-02-13 Parkinson’s disease
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended recruitment
  2024-514137-38-00 4 2025-02-04 Severe refractory idiopathic inflammatory myopathies (IIM)
• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended recruitment
  2024-510719-31-00 5 2025-01-24 Moderate to Severe Vasomotor Symptoms (VMS)
• A Study to Assess the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic … Ended recruitment
  2024-515026-86-00 4 2024-12-18 Refractory or Unexplained Chronic Cough
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended recruitment
  2024-511260-84-00 4 2024-09-03 Atopic Dermatitis
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves … Ended recruitment
  2023-507685-10-00 5 2024-05-30 High-Risk Non-muscle-invasive Bladder Cancer
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• Study of safety, tolerability and efficacy of DFV890 in adult participants with myeloid diseases Ended recruitment
  2022-501406-36-00 3 2023-12-14 Myeloid disease

Showing 169–192 of 288 trials